NasdaqCM:NKTRPharmaceuticals
Nektar Therapeutics (NKTR) Q3 Losses Narrow To US$35.5 Million Testing Bearish Narratives
Nektar Therapeutics (NKTR) kicked off FY 2025 with a third quarter that paired modest revenue with deep losses, reporting Q3 revenue of US$11.8 million, basic EPS of a US$1.87 loss and a net income loss of US$35.5 million. The company has seen quarterly revenue move from US$23.5 million in Q2 2024 and US$24.1 million in Q3 2024 to US$10.5 million, US$11.2 million and US$11.8 million over the first three quarters of 2025. Basic EPS shifted from a US$3.76 loss and US$2.66 loss in Q2 and Q3 2024...